Clover Biopharmaceuticals AUS Pty
Registry sponsor category
Industry
- Other names
- Clover Biopharmaceuticals AUS Pty
- Company name
- Clover Biopharmaceuticals AUS Pty
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (16)
- A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
- First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
- Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults
- Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults
- Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults
- Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
- Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.
- Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults
- Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases
- Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
- Safety and Immunogenicity Study of SCB-1019T in Children
- Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
- SCB-2019 as COVID-19 Vaccine
- Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
- Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions
- Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies